Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up

12 Sep 2018

• By Sten Stovall

Prospects rose for Galapagos and partner Gilead's JAK1 inhibitor with impressive Phase III FINCH 2 data in patients with moderate-to-severe rheumatoid arthritis.

Pivotal FINCH 2 Trial Gave Impressive Top-line Data In Rheumatoid Arthritis • Source: Shutterstock

Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up

More from Clinical Trials

More from R&D